Earlier this year, AZ fired another shot in bladder cancer when Imfinzi was cleared by the FDA alongside Bacillus ...
AstraZeneca’s $1.5 billion cost-savings drive has started to take a toll on its U.S. workforce. | AstraZeneca’s $1.5 billion cost-savings drive has started to take a toll on its U.S. workforce. The ...
The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...
With a positive classification from the DEA paving the way for Orzeyful’s U.S. launch on Thursday, Takeda is charting new ...
With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its ...
Following the blue tidal wave in the midterms that restored Democrats to power in both chambers of Congress, lawmakers on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results